Want to see KYTX full AI Analyst Report?
Kyverna Therapeutics, Inc. (KYTX) Income Statement
Kyverna Therapeutics, Inc. Income Statement
Last quarter (Q2 2026), Kyverna Therapeutics, Inc.'s total revenue was $0.00. In Q2, Kyverna Therapeutics, Inc.'s net income was $-38.32M. See Kyverna Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 7.03M | $ 5.66M | |
| $ 0.00 | $ -2.13M | $ -1.71M | $ 7.03M | $ 5.66M | |
| $ 169.83M | $ 140.47M | $ 60.70M | $ 36.41M | $ 32.00M | |
| Depreciation and Amortization | $ 1.80M | $ 2.13M | $ 1.71M | $ 1.05M | $ 586.00K |
| $ -159.02M | $ -125.20M | $ -58.47M | $ -27.78M | $ -25.76M | |
| $ -169.83M | $ -142.60M | $ -62.41M | $ -29.38M | $ -26.35M | |
| $ 8.52M | $ 15.13M | $ 2.04M | $ 491.00K | $ -4.00K | |
| $ -161.31M | $ -127.48M | $ -60.37M | $ -28.89M | $ -26.35M | |
| $ -161.31M | $ -127.48M | $ -60.37M | $ -28.89M | $ -26.35M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.64 | $ -3.33 | $ 0.00 | $ -1.12 | $ -1.02 |
| Diluted EPS | $ -3.64 | $ -3.33 | $ 0.00 | $ -1.12 | $ -1.02 |
| Weighted Average Shares Outstanding | 44.26M | 38.33M | 673.62M | 25.80M | 25.80M |
| Weighted Average Shares Outstanding (Diluted) | 44.26M | 38.33M | 673.62M | 25.80M | 25.80M |
Currency in USD
